Hematology Frontier

This article, published in the journal Blood Science, elucidates groundbreaking advancements in understanding the endothelial origins of the hematopoietic system. As a leading platform in clinical and experimental hematology, Blood Science continues to publish high-impact research that transforms molecular biology and physiology. Authored by Professor Yu Lan from the Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University and Professor Bing Liu from the Fifth Medical Center, Chinese PLA General Hospital, this study delves into the complex cellular evolution of hemogenic endothelial cells (HECs), the molecular mechanisms driving endothelial-to-hematopoietic transition (EHT), and the striking parallels between human and mouse systems. These insights mark a significant leap toward regenerative medicine and innovative treatments for hematological disorders.

New findings from the ECOG-ACRIN EA4151 Phase 3 trial, published in Blood on November 25, 2024, could change clinical practice for mantle cell lymphoma (MCL).For years, autologous hematopoietic cell transplantation…

New findings from the ECOG-ACRIN EA4151 Phase 3 trial, published in Blood on November 25, 2024, could change clinical practice for mantle cell lymphoma (MCL).For years, autologous hematopoietic cell transplantation…

Blood Science continues to lead the way in elucidating  complex biological processes and their implications in disease. In this insightful review article, “Dual role of BCL11B in T-cell malignancies,” Grzegorz K. Przybylski, Julia Przybylska, and Yangqiu Li explore the paradoxical functions of the B-cell CLL/lymphoma 11B (BCL11B) gene in T-cell development and malignancies.

This article, published in the esteemed journal Blood Science, explores the remarkable adaptability of megakaryocytes (MKs) in various physiological and pathological processes. Renowned for its pioneering work in hematology, Blood Science has showcased groundbreaking insights into the dynamic roles of MKs beyond their traditional function in platelet production, offering a deeper understanding of their involvement in immune modulation, aging, and hematological diseases.

From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, bringing together leading experts to discuss pivotal advances in hematology. Among the highlights was a groundbreaking study by Dr. Shanshan Pei and his team from The First Affiliated Hospital,Zhejiang University and Liangzhu Laboratory. This study (Abstract #38), selected for oral presentation, identified the rare fusion gene TFG-ROS1 as an oncogenic driver in human myeloid leukemia. Furthermore, the team demonstrated effective treatment strategies using ALK/ROS1 inhibitors, achieving remission in a patient with refractory leukemia after multiple treatment failures. This study exemplifies the “bench-to-bedside” paradigm in precision medicine, showcasing its transformative potential for cancer care. Below is an in-depth exploration of the study and exclusive insights from Professor Pei.

From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA. Experts and scholars from around the globe gathered to discuss and exchange insights on the latest research in hematology. During the conference, Dr. Bing Han from Peking Union Medical College provided an on-site review of two significant studies from the Severe Aplastic Anemia Working Party (EBMT-SAAWP) of the European Society for Blood and Marrow Transplantation. Professor Han also shared in-depth analyses of key research topics presented at the meeting. These highlights are summarized below for our readers.

In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth review of CAR-T cell therapy for B-cell lymphoma, summarizing approved CAR-T products, clinical trial data, real-world outcomes, and ongoing challenges. Additionally, this discussion explores strategies for enhancing CAR-T therapy, including novel targets, dual-target CAR-T designs, and gene-editing improvements, aiming to offer valuable insights for clinical practice and future research directions.

Thalassemia, an inherited blood disorder, imposes a significant economic and resource burden on patients, families, and society at large. In recent years, advances in medical research have led to a growing range of treatment options for thalassemia, including traditional blood transfusions and iron chelation therapy, drugs to induce gamma-globin production, hematopoietic stem cell transplantation (HSCT), and emerging approaches like gene and cell therapies, as well as nanomedicine. Among these, gene therapy has garnered particular attention as a potential cure, offering renewed hope to patients worldwide.

Significant progress has been made in the treatment of T-cell lymphomas in recent years. However, challenges persist in managing relapsed/refractory disease, selecting optimal therapies, and determining the best treatment sequencing for patients. To address these issues, the 2024 American Society of Hematology (ASH) Annual Meeting featured an educational session titled Addressing Unmet Needs in T-Cell Lymphomas. This session brought together leading experts to provide insights and practical guidance based on the latest research and clinical experiences. Hematology Frontier had the privilege of speaking with session chair Dr. Neha Mehta-Shah from Washington University’s Siteman Cancer Center. In this discussion, she shared her perspectives on unmet needs, treatment strategies for relapsed/refractory peripheral T-cell lymphoma (PTCL), innovative therapies, and the role of autologous and allogeneic transplants in PTCL.